SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PHAT

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$4.66-$0.42 (-8.27%)
 
Market cap
$379M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 25, 2019
Market Cap$378.82M-68.6%
Revenue (ttm)$274.88M+86.8%
Net Income-$83.00M+69.8%
EPS-$1.03+73.0%
Shares Out81.29M
PE Ration/a
Forward PE7.64
Dividendn/a
Ex-Dividend Daten/a
Volume1,330,427
Open$5.14
Previous Close$5.08
Day's Range$4.62 - $5.14
52-Week Range$4.62 - $18.31
Beta0.50
AnalystsBuy
Price Target$16.50(+254.08%)
Earnings DateFeb 25, 2027

About PHAT

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Address
100 Campus Drive, Florham Park, NJ, 07932, US
Market Cap
379 million
Employees
371
Industrial Classification
Biotechnology
Financial Health Score
Weak
From PHAT’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-8.27%
5 Days
-22.59%
1 Month
-33.52%
6 Months
-58.87%
1 Year
-68.56%

$PHAT stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in PHAT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PHAT's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PHAT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

PHAT Revenue by Segment

$102.89MTotal
Product revenue, net$84.72M82.34%
Stock-based compensation$18.17M17.66%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New PHAT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PHAT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in PHAT

VTIVanguard Morningstar Total Stock Market ETF$9.08M
IWMiShares Russell 2000 ETF$6.55M
XPHState Street SPDR S&P Pharmaceuticals ETF$4.29M
VXFVanguard Extended Market ETF$3.85M
IBBiShares Biotechnology ETF$2.02M
IWNiShares Russell 2000 Value ETF$1.69M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from PHAT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
45

News check: Mixed coverage with awareness campaign offset by significant stock decline; lacks concrete business catalysts or analyst actions.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SURISimplify Propel Opportunities ETF2.03%
XPHState Street SPDR S&P Pharmaceuticals ETF0.97%
BBPVirtus Biotech ETF0.78%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.17%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.14%
IWCiShares Micro-Cap ETF0.08%
IHEiShares U.S. Pharmaceuticals ETF0.07%
IBBQInvesco Nasdaq Biotechnology ETF0.03%
IBBiShares Biotechnology ETF0.02%
BIBProShares Ultra Nasdaq Biotechnology0.02%
VHTVanguard Health Care ETF0.01%
FHLCFidelity MSCI Health Care Index ETF0.00%

Weight is the stock’s share of each fund’s holdings.